Lupin Optimistic On Albuterol Given COVID-19 Demand

Metformin Batch Likely To Be Recalled

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Covid19_Lungs_Vial
Off-label Use Of Albuterol For COVID-19 Has Upped Demand • Source: Shutterstock

Lupin Ltd. expects a shortage of albuterol sulphate in the US, caused by the drug's off-label use in COVID-19 patients, to aid sales of its generic to Teva Pharmaceutical Industries Ltd.’s Proair on launch.

But while the Indian company might reap benefits from albuterol, a snowballing of concerns over nitrosamine impurities in metformin, coupled...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip